Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine with ECT for cognitive protection and EEG-based prediction of ECT response in depression
NL-OMON27806Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of rivastigmine in major depressive disorder (MDD), sponsored by University Medical Center Groningen. Primary endpoint: Cognitive and memory side effects after ECT. Started Sep 2021; status: recruiting.
02
Drugs
rivastigmine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON27806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27806.